PFIZER INC.

The American Health Care Association/National Center for Assisted Living launched the #GetVaccinated campaign to boost senior vaccination rates against respiratory viruses, despite vaccine fatigue and access barriers. The campaign includes best practices, factsheets, and resources on vaccine administration. LeadingAge partners with HHS’s ‘Risk Less. Do More.’ campaign to raise awareness. A survey found 37% of vaccinated individuals are hesitant to get shots this year, with payment issues complicating access in nursing homes. AHCA/NCAL and LeadingAge emphasize the importance of consistent vaccine recommendations to combat fatigue and mistrust.

BridgeBio, founded in 2015, has two products on the market and another awaiting FDA decision by November. The company is spinning out assets into new entities, discontinuing a gene therapy program, and focusing on late-stage programs in transthyretin amyloid cardiomyopathy and achondroplasia. BridgeBio aims to have six approved products by its tenth birthday, with a focus on commercializing its later-stage pipeline. The company’s success hinges on the approval and market performance of acoramidis for ATTR-CM and infigratinib for achondroplasia.

GSK's phase 2 data for its seasonal influenza mRNA vaccine, GSK4382276A, showed robust immune responses against A and B strains in older and younger adults, supporting progression to phase 3 trials. The vaccine demonstrated acceptable safety and reactogenicity profiles, aiming to develop a best-in-class vaccine for greater protection during flu season.

Novo Nordisk and Eli Lilly face competition from 16 new obesity drugs expected to launch by 2029, driving a $70 billion GLP-1 market by 2031. Price declines may accelerate over 10% annually by 2027. Rivals include Roche, Amgen, Pfizer, AstraZeneca, Boehringer, Viking Therapeutics, and Structure Therapeutics. The report predicts better efficacy, convenience, and tolerability for upcoming drugs.

Large drug-maker stocks surged, driven by FDA approvals and pipeline innovations. Eli Lilly, Roche, Novartis, and Pfizer are top picks for long-term gains. Eli Lilly's tirzepatide drugs and Novo Nordisk's semaglutide drugs are top sellers. Despite M&A scrutiny, activities remained strong. Large drug-makers offer robust revenue streams and profitability.

Moderna forecasts $2.5-$3.5B in 2024 sales, with 25% annual revenue growth from 2026-2028 driven by new product launches. The company anticipates 10 new product approvals by 2027, with meaningful revenue from 2028. Moderna plans to expand RSV vaccine approval to high-risk adults under 60 and focus on a COVID-influenza combination shot.

Moderna delays break-even goal to 2028, expects 2025 sales below 2024 forecast, and cuts R&D costs by $1.1 billion starting 2026. The company anticipates meaningful revenue from 10 new product approvals in 2028, reflecting uncertainty in COVID and RSV markets. Moderna plans to submit an FDA application for RSV shot expansion and focus on a COVID-influenza combination shot.

Moderna plans to cut $1.1 billion in expenses by 2027 and expects 10 new product approvals, including vaccines for RSV, flu, and norovirus, while pausing some R&D projects. The company aims for $3.6-3.8 billion in R&D spending by 2027, down from $4.8 billion expected this year, and targets a 25%+ CAGR from 2026 to 2028.